All In Biotech

Drug Trial Radar · NCT07914478

Role of Vitamin D Supplementation in Children With Irritable Bowel Syndrome

Role of Vitamin D Supplementation in Children With Irritable Bowel Syndrome: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Mar 30, 2027

Study completion Mar 30, 2027

Sponsor

Lead sponsor
Aziz Bhatti Shaheed Teaching HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to determine whether vitamin D supplementation improved symptoms in children with irritable bowel syndrome, a condition associated with repeated abdominal pain and changes in bowel habits. It was hypothesized that vitamin D supplementation would reduce symptom severity and increase blood vitamin D levels compared with placebo. The study was a randomized, placebo-controlled trial at the Department of Pediatrics, Aziz Bhatti Shaheed Teaching Hospital, Gujrat, Pakistan. It included 60 children aged 6-14 years who met established diagnostic criteria for irritable bowel syndrome and had low blood vitamin D levels of 10-29 ng/mL. Children were randomly assigned to two groups of 30 participants each. One group received oral vitamin D3 drops containing 2,000 international units once daily for 12 weeks. The other group received matching placebo drops without vitamin D for the same period. Both groups received routine supportive care, including advice on hydration, regular meals, diet, and symptom management. Follow-up visits were scheduled at 4, 8, and 12 weeks to assess symptoms, treatment adherence, and possible side effects. The main outcome was the change in symptom severity from the start of treatment to 12 weeks, measured using a standardized symptom score. The secondary outcome was the change in blood vitamin D levels over the same period. Changes in both outcomes were compared between the two groups.

Conditions

  • Irritable Bowel Syndrome (IBS)
  • Vitamin D Deficiency

Interventions

  • Vitamin D3Drug

    Vitamin D3 drops were administered orally at a dose of 2,000 international units once daily for 12 weeks, preferably after a meal, using a calibrated dropper. Standard supportive care included hydration advice, regular meals, dietary guidance according to symptoms, and parental home-care instructions.

  • PlaceboDrug

    Placebo drops were administered orally once daily for 12 weeks, matching the vitamin D3 drops in volume, appearance, and packaging. Participants received the same standard supportive care, including hydration advice, regular meals, dietary guidance according to symptoms, and parental home-care instructions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Irritable Bowel Syndrome Symptom Severity ScoreTime frame: Baseline and 12 weeks after treatment initiation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aziz Bhatti Shaheed Teaching Hospital

    Gujrat, Punjab Province, Pakistan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.